INT230-6 is currently undergoing phase 1/2 dose escalation in a clinical trial investigating repeating doses, dose frequency and drug load per tumor alone and in combination with a commercial PD-1 antibody (pembrolizumab) and a CTLA-4 antibody (ipilimumab) in several different refractory solid tumor cancers (NCT03058289). Here, CTLA4 is linked to neoplasm.